Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies.
The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Location: United States, New York, Buffalo
Employees: 201-500
Investors 2
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | Perceptive... | perceptive... |
Mentions in press and media 23
| Date | Title | Description | Source |
| 11.07.2022 | Struggling biotech sells its API manufacturing arm to n... | After a stock plunge in 2021 following a key FDA rejection, cancer biotech Athenex crashed in... | endpts.com... |
| 09.02.2022 | Athenex to Present at the 11th Annual SVB Leerink Global Hea... | BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmace... | marketscre... |
| 12.01.2022 | Athenex Announces Agreement with ImmunityBio Regarding Dunki... | BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmace... | marketscre... |
| 12.01.2022 | Athenex : Announces Agreement with ImmunityBio Regarding Dun... | Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility Buffalo, N.Y.... | marketscre... |
| 29.11.2021 | Athenex Announces UK MHRA Validation of the Marketing Author... | BUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmace... | marketscre... |
| 22.11.2021 | Athenex to Present Subgroup Analysis from Phase 3 Study of O... | Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk ... | marketscre... |
| 18.11.2021 | Athenex to Present at the Evercore ISI 4th Annual HealthCONx... | BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmace... | marketscre... |
| 04.11.2021 | Athenex Provides Third Quarter 2021 Corporate and Financial ... | Athenex Provides Third Quarter 2021 Corporate and Financial Update Held FDA Type A Meeting for oral... | marketscre... |
| 04.11.2021 | Athenex Provides Third Quarter 2021 Corporate and Financial ... | Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe... | marketscre... |
| 12.10.2021 | Athenex : Provides Update from FDA Type A Meeting Regarding ... | Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic... | marketscre... |
Show more